Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 27, 2023
Correction to: Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls.
Journal: Neurology and therapy
Published: May 04, 2022
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: January 12, 2022
Vitamin D Status and Clinical Outcomes in Acute Respiratory Distress Syndrome: A Secondary Analysis From the Assessment of Low Tidal Volume and Elevated End-Expiratory Volume to Obviate Lung Injury (ALVEOLI) Trial.
Journal: Journal of intensive care medicine
Published: June 24, 2021
The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study.
Journal: Orphanet journal of rare diseases
Published: December 22, 2020
Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay.
Journal: PloS one
Published: September 12, 2020
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Journal: CNS drugs
Published: August 18, 2019
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
Journal: Neuromuscular disorders : NMD
Published: February 26, 2019
Last Updated: 09/26/2026